menu
    • menu
    [{"orgOrder":0,"company":"Biotest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Trimodulin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Biotest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Biotest \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biotest \/ Not Applicable"},{"orgOrder":0,"company":"Biotest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Immune Globulin Intravenous, Human - Dira","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Biotest","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Biotest \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biotest \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Biotest

    Menu

    Biotest

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biotest

                            Germany arrow
                            CPhI India 2024
                            Not Confirmed

                            Biotest

                            Germany arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Immune Globulin Intravenous, Human - Dira

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Grifols’ Biotest: FDA Approves Yimmugo for Primary Immunodeficiencies

                            Details : Yimmugo is an innovative intravenous immunoglobulin (Ig) therapeutic, which is now approved for the treatment of patients with primary immunodeficiencies.

                            Brand Name : Yimmugo

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 17, 2024

                            Lead Product(s) : Immune Globulin Intravenous, Human - Dira

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biotest

                            Germany arrow
                            CPhI India 2024
                            Not Confirmed

                            Biotest

                            Germany arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trimodulin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Biotest AG: Biotest Treats First Covid-19 Patient with Trimodulin

                            Details : First patient with severe COVID-19 was treated in Spain with trimodulin in the ESsCOVID (Escape from severe COVID-19) trial. Biotest aims for an expedited approval of trimodulin to rapidly respond to the need for novel treatment options for patients with...

                            Brand Name : BT588

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 06, 2020

                            Lead Product(s) : Trimodulin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth